Associated Papers
Targeted treatment in a case series of AR+, HRAS/PIK3CA co-mutated salivary duct carcinoma.
Rieke DT et al.
Frontiers in Oncology, 2023
Direct molecular evidence for both multicentric and monoclonal carcinogenesis followed by transdifferentiation from hepatocellular carcinoma to cholangiocarcinoma in a case of metachronous liver cancer.
Ohni S et al.
Oncology Letters, 2022
34868359 (PubMed )
Supplement: Supplementary_Data2.xlsx › 173
Development and validation of a multigene variant profiling assay to guide targeted and immuno therapy selection in solid tumors.
Akolkar D et al.
Plos One, 2021
33556149 (PubMed )
Supplement: pone.0246048.s008.xlsx › Sheet1
Excellent Response With Alpelisib and Bicalutamide for Advanced Salivary Duct Carcinoma With PIK3CA Mutation and High Androgen Receptor Expression-A Case Report.
Sheth H et al.
Jco Precision Oncology, 2021
The evolutionary pattern of mutations in glioblastoma reveals therapy-mediated selection.
Muscat AM et al.
Oncotarget, 2018
29487696 (PubMed )
Supplement: oncotarget-09-7844-s003.xlsx › Supplementary_Table_S2
Targeted sequencing-based analyses of candidate gene variants in ulcerative colitis-associated colorectal neoplasia.
Chakrabarty S et al.
British Journal of Cancer, 2017
Select a paper to view details